Praxis Receives FDA Priority Review for Relutrigine
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 30 2026
0mins
Source: Newsfilter
- FDA Review Progress: Praxis Precision Medicines announced that its New Drug Application (NDA) has been accepted for priority review by the FDA, with a target action date of September 27, 2026, marking a significant milestone in the company's evolution towards commercialization, as approval would make it the first disease-modifying therapy for SCN2A and SCN8A developmental epileptic encephalopathies.
- Clinical Trial Results: The NDA is supported by positive results from the EMBOLD study, which was stopped early for efficacy, demonstrating significant therapeutic effects of relutrigine in patients with severe epilepsy, potentially improving their quality of life.
- Drug Designations: Relutrigine has received Orphan Drug, Rare Pediatric Disease, and Breakthrough Therapy designations from the FDA, and if approved, it will be eligible for a Pediatric Review Voucher, enhancing its competitive position in the market.
- Future Research Plans: The drug is also being investigated in the EMERALD trial for broader DEEs, expected to be completed by the end of 2026, showcasing Praxis's ongoing innovation and commitment in the epilepsy treatment space.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRAX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRAX
Wall Street analysts forecast PRAX stock price to rise
15 Analyst Rating
14 Buy
0 Hold
1 Sell
Strong Buy
Current: 352.630
Low
95.00
Averages
456.71
High
843.00
Current: 352.630
Low
95.00
Averages
456.71
High
843.00
About PRAX
Praxis Precision Medicines, Inc. is an integrated, central nervous system (CNS) precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is a targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company's product candidates include Ulixacaltamide, Vormatrigine, Relutrigine, PRAX-080, Elsunersen, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
B Group Acquires Stake in Bright Minds Biosciences
- New Investment Position: B Group disclosed in its May 15, 2026 SEC filing that it acquired 67,500 shares of Bright Minds Biosciences for an estimated $5.43 million, indicating confidence in the company's future growth potential.
- Significant Stake: This acquisition represents approximately 4% of B Group's reportable AUM, reflecting its strategic positioning within the biotechnology sector.
- Strong Market Performance: Bright Minds' shares have surged nearly 175% over the past year, significantly outperforming the S&P 500's 25% increase, highlighting market confidence in its drug development prospects.
- Increased R&D Investment: Bright Minds ramped up its R&D spending to C$18.7 million in the first half of fiscal 2026, a substantial increase from C$3.6 million a year earlier, demonstrating accelerated efforts in developing its lead drug BMB-101 for drug-resistant epilepsy.
See More
HighVista Strategies Cuts Stake in Viridian Therapeutics by $7 Million
- Stake Reduction Details: HighVista Strategies reported a sale of 238,243 shares of Viridian Therapeutics in its SEC filing dated May 15, 2026, representing an estimated $7.08 million trade, indicating a cautious outlook on the company's future performance.
- Impact of Stock Price Fluctuations: Despite Viridian Therapeutics' stock price rising 35% over the past year, the value of its position declined by $8.97 million at quarter-end, reflecting market concerns regarding the upcoming FDA decision.
- Company Financial Overview: Viridian's latest financial report indicates a revenue of $70.85 million and a net loss of $342.6 million over the trailing twelve months, highlighting the financial pressures faced during its development phase, which may affect investor confidence.
- Market Outlook and Challenges: With an FDA decision looming on June 30 for its lead therapy, Viridian's market performance may be impacted, especially after its Phase 3 clinical data fell short of expectations, prompting investors to carefully assess risks and opportunities.
See More
Praxis Precision Medicines FDA Accepts New Drug Application for Ulixacaltamide
- FDA Application Progress: Praxis Precision Medicines' new drug application for ulixacaltamide HCl has been accepted for review by the FDA, marking a significant advancement in addressing essential tremor, a common movement disorder affecting nearly 7 million Americans, which is expected to enhance the company's market competitiveness.
- Clinical Trial Success: The application is supported by data from the company's Essential3 Phase 3 clinical trials, where two pivotal studies met their primary endpoints, demonstrating statistically and clinically significant results for ulixacaltamide in adults with essential tremor, further strengthening its market outlook.
- Target Action Date: The FDA has set January 29, 2027, as the target action date for the new drug application and has not indicated plans for an advisory committee meeting, which could expedite the approval process and boost investor confidence.
- Positive Market Reaction: Praxis's stock rose approximately 6% in premarket trading, reflecting investor optimism regarding the FDA's acceptance of the application, signaling potential future growth for the company.
See More
Praxis Precision Medicines' NDA for Ulixacaltamide Accepted by FDA
- FDA Review Acceptance: Praxis Precision Medicines announced that its New Drug Application (NDA) for ulixacaltamide HCl for treating essential tremor in adults has been accepted for review by the FDA, marking a significant advancement in the company's therapeutic pipeline.
- Key Timeline: The FDA has set a target action date of January 29, 2027, under the Prescription Drug User Fee Act (PDUFA), indicating that the company will face a critical regulatory review phase in its development plans over the coming years.
- Clinical Trial Support: The NDA submission is backed by positive results from the Essential3 Phase 3 clinical program, which included two concurrently enrolled pivotal studies demonstrating statistically and clinically significant efficacy, laying a solid foundation for the drug's market potential.
- Good Safety Profile: Ulixacaltamide was generally well tolerated in clinical trials, with a safety profile consistent with previous studies and no drug-related serious adverse events reported, enhancing the likelihood of FDA approval.
See More
Praxis Receives FDA Review Acceptance for Ulixacaltamide NDA
- FDA Review Progress: Praxis Precision Medicines announced that its New Drug Application for ulixacaltamide HCl for treating essential tremor in adults has been accepted for review by the FDA, with a target action date set for January 29, 2027, marking a significant milestone in the company's CNS drug development.
- Clinical Trial Support: The NDA is supported by positive results from the Essential3 Phase 3 clinical trials, which demonstrated statistically and clinically significant efficacy of ulixacaltamide in treating essential tremor, further enhancing its market potential.
- Good Safety Profile: Ulixacaltamide exhibited good tolerability in clinical trials, with a safety profile consistent with previous studies and no drug-related serious adverse events, laying a solid foundation for its future commercialization.
- Breakthrough Therapy Designation: The drug received Breakthrough Therapy Designation from the FDA in December 2025, highlighting its innovation and market demand in treating essential tremor, as Praxis continues to collaborate with the FDA in preparation for its commercial launch.
See More
PRAXIS PRECISION MEDICINES INC: RAYMOND JAMES BEGINS COVERAGE WITH A STRONG BUY RATING AND A TARGET PRICE OF $815
Company Overview: Praxis Precision Medicines is highlighted for its strong buy rating, indicating positive investor sentiment and confidence in the company's future performance.
Target Price: The target price for Praxis Precision Medicines is set at $815, suggesting significant potential for growth based on current market evaluations.
See More
B Group Acquires Stake in Bright Minds Biosciences
- New Investment Position: B Group disclosed in its May 15, 2026 SEC filing that it acquired 67,500 shares of Bright Minds Biosciences for an estimated $5.43 million, indicating confidence in the company's future growth potential.
- Significant Stake: This acquisition represents approximately 4% of B Group's reportable AUM, reflecting its strategic positioning within the biotechnology sector.
- Strong Market Performance: Bright Minds' shares have surged nearly 175% over the past year, significantly outperforming the S&P 500's 25% increase, highlighting market confidence in its drug development prospects.
- Increased R&D Investment: Bright Minds ramped up its R&D spending to C$18.7 million in the first half of fiscal 2026, a substantial increase from C$3.6 million a year earlier, demonstrating accelerated efforts in developing its lead drug BMB-101 for drug-resistant epilepsy.
See More
HighVista Strategies Cuts Stake in Viridian Therapeutics by $7 Million
- Stake Reduction Details: HighVista Strategies reported a sale of 238,243 shares of Viridian Therapeutics in its SEC filing dated May 15, 2026, representing an estimated $7.08 million trade, indicating a cautious outlook on the company's future performance.
- Impact of Stock Price Fluctuations: Despite Viridian Therapeutics' stock price rising 35% over the past year, the value of its position declined by $8.97 million at quarter-end, reflecting market concerns regarding the upcoming FDA decision.
- Company Financial Overview: Viridian's latest financial report indicates a revenue of $70.85 million and a net loss of $342.6 million over the trailing twelve months, highlighting the financial pressures faced during its development phase, which may affect investor confidence.
- Market Outlook and Challenges: With an FDA decision looming on June 30 for its lead therapy, Viridian's market performance may be impacted, especially after its Phase 3 clinical data fell short of expectations, prompting investors to carefully assess risks and opportunities.
See More
Praxis Precision Medicines FDA Accepts New Drug Application for Ulixacaltamide
- FDA Application Progress: Praxis Precision Medicines' new drug application for ulixacaltamide HCl has been accepted for review by the FDA, marking a significant advancement in addressing essential tremor, a common movement disorder affecting nearly 7 million Americans, which is expected to enhance the company's market competitiveness.
- Clinical Trial Success: The application is supported by data from the company's Essential3 Phase 3 clinical trials, where two pivotal studies met their primary endpoints, demonstrating statistically and clinically significant results for ulixacaltamide in adults with essential tremor, further strengthening its market outlook.
- Target Action Date: The FDA has set January 29, 2027, as the target action date for the new drug application and has not indicated plans for an advisory committee meeting, which could expedite the approval process and boost investor confidence.
- Positive Market Reaction: Praxis's stock rose approximately 6% in premarket trading, reflecting investor optimism regarding the FDA's acceptance of the application, signaling potential future growth for the company.
See More
Praxis Precision Medicines' NDA for Ulixacaltamide Accepted by FDA
- FDA Review Acceptance: Praxis Precision Medicines announced that its New Drug Application (NDA) for ulixacaltamide HCl for treating essential tremor in adults has been accepted for review by the FDA, marking a significant advancement in the company's therapeutic pipeline.
- Key Timeline: The FDA has set a target action date of January 29, 2027, under the Prescription Drug User Fee Act (PDUFA), indicating that the company will face a critical regulatory review phase in its development plans over the coming years.
- Clinical Trial Support: The NDA submission is backed by positive results from the Essential3 Phase 3 clinical program, which included two concurrently enrolled pivotal studies demonstrating statistically and clinically significant efficacy, laying a solid foundation for the drug's market potential.
- Good Safety Profile: Ulixacaltamide was generally well tolerated in clinical trials, with a safety profile consistent with previous studies and no drug-related serious adverse events reported, enhancing the likelihood of FDA approval.
See More
Praxis Receives FDA Review Acceptance for Ulixacaltamide NDA
- FDA Review Progress: Praxis Precision Medicines announced that its New Drug Application for ulixacaltamide HCl for treating essential tremor in adults has been accepted for review by the FDA, with a target action date set for January 29, 2027, marking a significant milestone in the company's CNS drug development.
- Clinical Trial Support: The NDA is supported by positive results from the Essential3 Phase 3 clinical trials, which demonstrated statistically and clinically significant efficacy of ulixacaltamide in treating essential tremor, further enhancing its market potential.
- Good Safety Profile: Ulixacaltamide exhibited good tolerability in clinical trials, with a safety profile consistent with previous studies and no drug-related serious adverse events, laying a solid foundation for its future commercialization.
- Breakthrough Therapy Designation: The drug received Breakthrough Therapy Designation from the FDA in December 2025, highlighting its innovation and market demand in treating essential tremor, as Praxis continues to collaborate with the FDA in preparation for its commercial launch.
See More
PRAXIS PRECISION MEDICINES INC: RAYMOND JAMES BEGINS COVERAGE WITH A STRONG BUY RATING AND A TARGET PRICE OF $815
Company Overview: Praxis Precision Medicines is highlighted for its strong buy rating, indicating positive investor sentiment and confidence in the company's future performance.
Target Price: The target price for Praxis Precision Medicines is set at $815, suggesting significant potential for growth based on current market evaluations.
See More
